JP2021519308A5 - - Google Patents
Info
- Publication number
- JP2021519308A5 JP2021519308A5 JP2020551963A JP2020551963A JP2021519308A5 JP 2021519308 A5 JP2021519308 A5 JP 2021519308A5 JP 2020551963 A JP2020551963 A JP 2020551963A JP 2020551963 A JP2020551963 A JP 2020551963A JP 2021519308 A5 JP2021519308 A5 JP 2021519308A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- groups
- cancer
- alkoxy
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650151P | 2018-03-29 | 2018-03-29 | |
| US62/650,151 | 2018-03-29 | ||
| PCT/US2019/024976 WO2019191667A1 (en) | 2018-03-29 | 2019-03-29 | Imidazopiperazine inhibitors of transcription activating proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021519308A JP2021519308A (ja) | 2021-08-10 |
| JP2021519308A5 true JP2021519308A5 (cg-RX-API-DMAC7.html) | 2022-03-30 |
| JP7387627B2 JP7387627B2 (ja) | 2023-11-28 |
Family
ID=68057632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551963A Active JP7387627B2 (ja) | 2018-03-29 | 2019-03-29 | 転写活性化タンパク質のイミダゾピペラジン阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11058688B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3773587A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7387627B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102815607B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112165944B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019245403B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020019824A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3095367A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL277628A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2020131507A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019191667A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202006092B (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3095367A1 (en) | 2018-03-29 | 2019-10-03 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| WO2019195846A1 (en) | 2018-04-06 | 2019-10-10 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
| US12486251B2 (en) | 2020-04-25 | 2025-12-02 | Pharmablock Sciences (Nanjing) , Inc. | CBP/EP300 inhibitor and use thereof |
| KR20230080441A (ko) * | 2020-10-02 | 2023-06-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 전사 활성화 단백질의 이미다조피페라진 억제제 |
| JP7777131B2 (ja) * | 2020-10-02 | 2025-11-27 | ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム | 転写活性化タンパク質のイミダゾピペラジン阻害剤 |
| US20240122941A1 (en) * | 2020-12-25 | 2024-04-18 | National Cancer Center | Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer |
| JP7746406B2 (ja) * | 2021-04-21 | 2025-09-30 | 長春金賽薬業有限責任公司 | イミダゾール含有縮合環系誘導体、その調製方法及びその医薬上の応用 |
| CN113429427A (zh) * | 2021-07-05 | 2021-09-24 | 湖南南新制药股份有限公司 | 杂环化合物及其制备方法和药物用途 |
| CA3228746A1 (en) * | 2021-08-25 | 2023-03-02 | Qiaojun HE | Aromatic heterocyclic compound, pharmaceutical composition containing the same, and use thereof |
| CN116410211A (zh) * | 2021-12-29 | 2023-07-11 | 山东新时代药业有限公司 | 一种苯并呋喃类化合物 |
| WO2023138674A1 (zh) * | 2022-01-21 | 2023-07-27 | 默达药物(香港)有限公司 | N-羟基喹啉甲酰胺化合物及其用途 |
| US20230391786A1 (en) * | 2022-06-02 | 2023-12-07 | Eli Lilly And Company | cGAS INHIBITORS |
| AU2024387082A1 (en) | 2023-11-21 | 2026-06-04 | Fmc Corporation | Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides |
| TW202542135A (zh) | 2024-01-17 | 2025-11-01 | 南韓商Lg化學股份有限公司 | 作為CBP/p300抑制劑之新穎化合物和含有彼作為活性成分以預防或治療癌症、發炎病症或自體免疫疾病之醫藥組成物 |
| KR20250113346A (ko) | 2024-01-17 | 2025-07-25 | 주식회사 엘지화학 | CBP/p300 저해제로 사용되는 신규 화합물, 및 이를 유효성분으로 포함하는 암, 염증성 장애 또는 자가면역 질환의 예방 또는 치료용 약학 조성물 |
| CN122535608A (zh) | 2024-01-17 | 2026-08-07 | 株式会社Lg化学 | 用作cbp/p300抑制剂的新型化合物以及包含其作为活性成分的用于预防或治疗癌症、炎性障碍或自身免疫性疾病的药物组合物 |
| WO2026128761A1 (en) | 2024-12-11 | 2026-06-18 | Nexo Therapeutics, Inc. | Covalent p300 inhibitor compounds |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2270143T3 (es) | 2002-08-07 | 2007-04-01 | Novartis Ag | Compuestos organicos como agentes para el tratamiento de condiciones mediadas por aldosterona. |
| US20070004736A1 (en) | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
| WO2007139992A2 (en) | 2006-05-26 | 2007-12-06 | Novartis Ag | ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS |
| US7943617B2 (en) * | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
| AU2007337659A1 (en) * | 2006-12-22 | 2008-07-03 | Actelion Pharmaceuticals Ltd. | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives |
| US8859538B2 (en) | 2007-06-21 | 2014-10-14 | Cara Therapeutics, Inc. | Uses of substituted imidazoheterocycles |
| EA201000046A1 (ru) * | 2007-06-21 | 2011-02-28 | Кара Терапеутикс, Инк. | Замещенные имидазогетероциклы |
| CN101417999A (zh) * | 2007-10-25 | 2009-04-29 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| CN101468988A (zh) | 2007-12-26 | 2009-07-01 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| KR20110036069A (ko) | 2008-06-25 | 2011-04-06 | 액테리온 파마슈티칼 리미티드 | 5,6,7,8-테트라히드로-이미다조[1,5-a]피라진 화합물 |
| PE20120121A1 (es) * | 2008-12-08 | 2012-02-20 | Gilead Connecticut Inc | Derivados de imidazopirazina como inhibidores de syk |
| WO2011092120A1 (en) | 2010-01-29 | 2011-08-04 | Nerviano Medical Sciences S.R.L. | 6,7- dihydroimidazo [1,5-a] pyrazin-8 (5h) - one derivatives as protein kinase modulators |
| CN102372716A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| WO2013050446A1 (en) | 2011-10-07 | 2013-04-11 | Nerviano Medical Sciences S.R.L. | SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS |
| CN103087067A (zh) * | 2012-08-02 | 2013-05-08 | 盛世泰科生物医药技术(苏州)有限公司 | 作为二肽基酶抑制剂的化合物及其组合物,以及它们的用途 |
| WO2014062548A1 (en) | 2012-10-18 | 2014-04-24 | Bristol-Myers Squibb Company | Tetrahydroimdidazopyrazine derivatives as cgrp receptor antagonists |
| CA2915163A1 (en) * | 2013-06-12 | 2014-12-18 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| HK1223364A1 (zh) * | 2013-06-28 | 2017-07-28 | Abbvie Inc. | 布罗莫结构域抑制剂 |
| CN107108512B (zh) | 2014-10-10 | 2021-05-04 | 基因泰克公司 | 治疗性化合物及其用途 |
| EP3632915A1 (en) * | 2014-11-27 | 2020-04-08 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| AU2017252276A1 (en) | 2016-04-18 | 2018-11-15 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
| WO2017205536A2 (en) * | 2016-05-24 | 2017-11-30 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| MA45146A (fr) * | 2016-05-24 | 2021-03-24 | Constellation Pharmaceuticals Inc | Dérivés de pyrazolopyridine pour le traitement du cancer |
| CA3095367A1 (en) | 2018-03-29 | 2019-10-03 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| WO2019195846A1 (en) | 2018-04-06 | 2019-10-10 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
-
2019
- 2019-03-29 CA CA3095367A patent/CA3095367A1/en active Pending
- 2019-03-29 RU RU2020131507A patent/RU2020131507A/ru unknown
- 2019-03-29 EP EP19777484.7A patent/EP3773587A4/en active Pending
- 2019-03-29 JP JP2020551963A patent/JP7387627B2/ja active Active
- 2019-03-29 BR BR112020019824-2A patent/BR112020019824A2/pt not_active Application Discontinuation
- 2019-03-29 AU AU2019245403A patent/AU2019245403B2/en active Active
- 2019-03-29 KR KR1020207031004A patent/KR102815607B1/ko active Active
- 2019-03-29 US US16/370,404 patent/US11058688B2/en active Active
- 2019-03-29 CN CN201980035368.2A patent/CN112165944B/zh active Active
- 2019-03-29 WO PCT/US2019/024976 patent/WO2019191667A1/en not_active Ceased
-
2020
- 2020-09-27 IL IL277628A patent/IL277628A/en unknown
- 2020-10-01 ZA ZA2020/06092A patent/ZA202006092B/en unknown
-
2021
- 2021-05-21 US US17/327,217 patent/US12186324B2/en active Active
-
2024
- 2024-11-06 US US18/938,730 patent/US20250127792A1/en active Pending
-
2025
- 2025-04-29 AU AU2025202971A patent/AU2025202971A1/en active Pending